A product of Sunlight Foundation

Novartis Corp

Parent Organization: Novartis AG

Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry.[when?] Company sales totalled 36.173 billon US$ in 2008. Currently,[when?] Novartis is the sixth largest pharmaceutical company in terms of revenue ($41.5 billion in 2009) with a profit margin of about 20%, which is the same as its industry competitors. Novartis profits were down by 31% from 2007 levels. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's December 31, 2012 filing.
  • Summary

    overview of the committee's finances
    Total Raised:
    $713,785
    Total Spent:
    $644,312
    Cash on Hand:
    $202,800
    Debts:
    $0

Standardized Donation Information

covers roughly through Q4 2013. may lag behind FEC section above, as donors and industries are identified by hand.
  • Top Recipients

    PAC Color Block
    Organization's PAC(s)
    Employee Color Block
    Associated Individuals
    Includes contributions from the organization’s employees, their family members, and its political action committee.
  • Republicans vs. Democrats

    in dollars
  • State vs. Federal

    in dollars
  • Top PAC Recipients

    PAC Color Block
    Organization's PAC(s)
    Employee Color Block
    Associated Individuals
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Novartis Corp Sources: OpenSecrets.org

Lobbying

$13,701,136 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers roughly through Q3, 2013

Lobbying on Behalf of Novartis Corp

  • Names of Lobbyists
  • Firm Hired Amount
    Novartis Corp $13,701,136
  • Most Frequently Disclosed Lobbying Issues
    • Health Issues,
    • Fed Budget & Appropriations,
    • Medicare & Medicaid,
    • Taxes,
    • Copyright, Patent & Trademark,
    • Government Issues,
    • Medical Research & Clin Labs,
    • Trade,
    • Labor, Antitrust & Workplace,
    • Animals
  • Most Frequently Disclosed Bills
    Bill No. Title
    S.23 Patent Reform Act of 2011
    H.R.452 Medicare Decisions Accountability Act of 2011
    H.R.3590 Service Members Home Ownership Tax Act of 2009
    H.R.2245 Preserving Access to Life-Saving Medications Act of 2011
    S.27 Preserve Access to Affordable Generics Act
    H.R.1 Full-Year Continuing Appropriations Act, 2011
    H.R.1548 Right to Rent Act of 2011
    H.R.276 To amend title 38, United States Code, to allow for the transfer of educational assistance under the Post-9/11 Educational Assistance Program to certain dependents to be used for special education.
    H.R.1458 Law Student Clinic Participation Act of 2011
    H.R.2746 Cancer Drug Coverage Parity Act of 2011
  • Recent Lobbying Contracts
    Date Registrant Summary
    April 7, 2014 East End Group, LLC Medicare and Medicaid implementation, Food and Drug regulation, and public health issues. View registration
View all lobbying data for Novartis Corp Sources: Lobbyist Registration Tracker OpenSecrets.org

Regulations

Mentioned in 12 dockets; Submitted to 3 dockets
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated daily from Regulations.gov by way of Docket Wrench

The tables show occurrences of "Novartis Corp" in public comments on proposed federal regulations.